Opinion

Video

The Role of HER2 in Breast Cancer and Treatment Goals for HER+ Metastatic Breast Cancer Patients

Author(s):

Tiffany A. Traina, MD,VK Gadi, MD, PhD

Tiffany A. Traina, MD; Vijayakrishna Gadi, MD, PhD, and Heather McArthur, MD, underscore the importance of testing all early-stage and breast cancer patients for HER2 positivity to inform and guide optimal therapeutic decision-making.

Related Videos
Alexis LeVee, MD
2 expert is featured in this series.
2 experts in this video
2 experts in this video
Related Content
Kelly K. Hunt, MD, FACS, FSSO, of MD Anderson Cancer Center
January 3rd 2025

One Surgeon’s Spirit and Brilliance Lift a Whole Community

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

NCCN: Image by Kellie Ehrmann/MJH Life Sciences using AI
December 31st 2024

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies

James J. Harding, MD, director, Early Drug Development, Memorial Sloan Kettering Cancer Center
December 30th 2024

FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer

Carol Aghajanian, MD, of Memorial Sloan Kettering Cancer Center
December 28th 2024

Shaking Up Gynecologic Cancer Treatment With Mentorship and Patient-Centric Care

Felipe Batalini, MD, of Mayo Clinic
December 26th 2024

Allosteric Inhibitors Targeting PIK3CA May Reduce Treatment Toxicities in Breast Cancer